On October 5, 2022 Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target solid tumors, reported that the SITC (Free SITC Whitepaper) abstract review committee has selected the ONCOS-102 phase 1b study in PD-1 resistant advanced melanoma for oral presentation at the annual meeting to be held in November in Boston (Press release, Targovax, OCT 5, 2022, View Source [SID1234621726]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
PD-1 checkpoint inhibitor (CPI) resistant advanced melanoma is a major unmet medical need affecting up to 25,000 patients per year in the major markets. The diagnosis is associated with a poor prognosis and there are currently no approved treatment options available.
In an earlier topline data release from this Phase 1b study, Targovax reported an encouraging objective response rate (ORR) of 35% for the combination of ONCOS-102 and the PD-1 CPI Keytruda. At the SITC (Free SITC Whitepaper) conference, further translational biomarker analyses and the impact of dosing regimen on systemic activity and immune responses will be presented.
Title of the abstract, to be presented both orally and as a poster:
Presenter: Dr. Alexander Shoushtari, Principal Investigator, Memorial Sloan Kettering Cancer Center, NYC
Title: Repeat dosing of oncolytic adenovirus ONCOS-102 is associated with enhanced and persistent immune responses and improved systemic activity in anti-PD-1 resistant/refractory (r/r) melanoma
Date: 10 November, 2022
Time: 7pm ET
Dr. Lone Ottesen, Chief Medical Officer of Targovax ASA, said: "It is a great honor to have our study selected for an oral presentation at the SITC (Free SITC Whitepaper) annual meeting, which is considered the most prestigious scientific forum in cancer immunotherapy. The podium presentation will be given by principal investigator Dr. Alexander Shoushtari from the Memorial Sloan Kettering Cancer Center in New York, and provides an excellent opportunity to showcase the strong ONCOS-102 melanoma data package to a broad, international audience of academic leaders".